Literature DB >> 23346902

Screening for X-linked adrenoleukodystrophy among adult men with Addison's disease.

Morten A Horn1, Martina M Erichsen, Anette S B Wolff, Jan-Eric Månsson, Eystein S Husebye, Chantal M E Tallaksen, Ola H Skjeldal.   

Abstract

OBJECTIVES: X-linked adrenoleukodystrophy is an important cause of Addison's disease in boys, but less is known about its contribution to Addison's disease in adult men. After surveying all known cases of X-linked adrenoleukodystrophy in Norway in a separate study, we aimed to look for any missed cases among the population of adult men with nonautoimmune Addison's disease. STUDY
DESIGN: Among 153 adult men identified in a National Registry for Addison's Disease (75% of identified male cases of Addison's disease in Norway), those with negative indices for 21-hydroxylase autoantibodies were selected. Additionally, cases with low autoantibody indices (48-200) were selected. Sera from subjects included were analysed for levels of very long-chain fatty acids, which are diagnostic for X-linked adrenoleukodystrophy in men.
RESULTS: Eighteen subjects had negative indices and 17 had low indices for 21-hydroxylase autoantibodies. None of those with low indices and only one of those with negative indices were found to have X-linked adrenoleukodystrophy; this subject had already been diagnosed because of the neurological symptoms. Cases of Addison's disease proved to be caused by X-linked adrenoleukodystrophy constitute 1·5% of all adult male cases in Norway; the proportion among nonautoimmune cases was 15%.
CONCLUSIONS: We found X-linked adrenoleukodystrophy to be an uncommon cause of Addison's disease in adult men. However, this aetiological diagnosis has far-reaching consequences both for the patient and for his extended family. We therefore recommend that all adult men with nonautoimmune Addison's disease be analysed for levels of very long-chain fatty acids.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23346902     DOI: 10.1111/cen.12159

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

Review 1.  X-linked adrenoleukodystrophy: pathogenesis and treatment.

Authors:  Marc Engelen; Stephan Kemp; Bwee-Tien Poll-The
Journal:  Curr Neurol Neurosci Rep       Date:  2014-10       Impact factor: 5.081

Review 2.  Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history.

Authors:  Stephan Kemp; Irene C Huffnagel; Gabor E Linthorst; Ronald J Wanders; Marc Engelen
Journal:  Nat Rev Endocrinol       Date:  2016-06-17       Impact factor: 43.330

3.  Identification of Two Novel Mutations of ABCD1 Gene in Pedigrees with X-Linked Adrenoleukodystrophy and Review of the Literature.

Authors:  Bingzi Dong; Wenshan Lv; Lili Xu; Yuhang Zhao; Xiaofang Sun; Zhongchao Wang; Bingfei Cheng; Zhengju Fu; Yangang Wang
Journal:  Int J Endocrinol       Date:  2022-02-07       Impact factor: 2.803

Review 4.  Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline.

Authors:  Stefan R Bornstein; Bruno Allolio; Wiebke Arlt; Andreas Barthel; Andrew Don-Wauchope; Gary D Hammer; Eystein S Husebye; Deborah P Merke; M Hassan Murad; Constantine A Stratakis; David J Torpy
Journal:  J Clin Endocrinol Metab       Date:  2016-01-13       Impact factor: 5.958

5.  An unusual presentation of X-linked adrenoleukodystrophy.

Authors:  Avinash Suryawanshi; Timothy Middleton; Kirtan Ganda
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2015-11-03

6.  Defining diagnostic cutoffs in neurological patients for serum very long chain fatty acids (VLCFA) in genetically confirmed X-Adrenoleukodystrophy.

Authors:  Tim W Rattay; Maren Rautenberg; Anne S Söhn; Holger Hengel; Andreas Traschütz; Benjamin Röben; Stefanie N Hayer; Rebecca Schüle; Sarah Wiethoff; Lena Zeltner; Tobias B Haack; Alexander Cegan; Ludger Schöls; Erwin Schleicher; Andreas Peter
Journal:  Sci Rep       Date:  2020-09-15       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.